Drug_Name,STUDYID,YEAR,Country,Dataset,Patient_Count,Median_Age,Female_Percentage,Male_Percentage,Median_BMI,Smoking_History_Yes_Percentage,Total_ADL_Independence_Percentage,LHRH_Use_Percentage,Tumor_Stage_T1_Percentage,Tumor_Stage_T2_Percentage,Tumor_Stage_T3_Percentage,Tumor_Stage_T4_Percentage,Nodal_Stage_N0_Percentage,Nodal_Stage_N1_Percentage,Nodal_Stage_N2_Percentage,Nodal_Stage_N3_Percentage,Stage_I_Percentage,Stage_II_Percentage,Stage_III_Percentage,Diabetes_Mellitus_Percentage,Congestive_Heart_Failure_Percentage,Stroke_Percentage,Atrial_Fibrillation_Percentage,Myocardial_Infarction_Percentage,Neoadjuvant_Chemotherapy_Received_Percentage,Adjuvant_Chemotherapy_Received_Percentage,Postoperative_RT_Received_Percentage,Common_Neoadjuvant_Regimen_1,Common_Neoadjuvant_Regimen_2,Common_Adjuvant_Regimen_1,Common_Adjuvant_Regimen_2,Tamoxifen_Percentage,Letrozole_Percentage,Anastrozole_Percentage,Antidiarrheal_Agent_Probiotics_Percentage,Antiemetic_Agent_Percentage,Painkiller_Antipyretic_Percentage,Beds_Less_Than_200_Percentage,Beds_200_To_499_Percentage,Beds_Greater_Or_Equal_To_500_Percentage,Designated_Cancer_Hospital_Percentage,Months_Between_Surgery_And_Index_Date
Olaparib,OLA2023-US,2023,USA,MDV,350,62,98,2,27.5,15,85,5,10,35,40,15,60,25,10,5,15,40,30,12,3,2,5,1,20,55,40,Taxol + Carboplatin,AC (Adriamycin + Cyclophosphamide),TC (Taxotere + Cyclophosphamide),"FEC (5-FU, Epirubicin, Cyclophosphamide)",30,25,20,45,60,70,10,45,45,60,2
Olaparib,OLA2022-UK,2022,UK,Claim Database,420,68,97,3,28.1,22,78,7,12,38,35,15,55,30,10,5,18,35,32,15,5,3,7,2,25,60,45,EC (Epirubicin + Cyclophosphamide),"CMF (Cyclophosphamide, Methotrexate, 5-FU)",Docetaxel + Cyclophosphamide,"AC-T (Adriamycin, Cyclophosphamide followed by Taxol)",35,20,15,50,65,75,15,40,45,55,3
Olaparib,OLA2024-CA,2024,Canada,MDV,280,65,99,1,26.8,18,82,6,8,32,45,15,65,20,10,5,12,45,28,10,4,1,6,1,18,50,35,AC (Adriamycin + Cyclophosphamide),Taxol + Cyclophosphamide,"FEC (5-FU, Epirubicin, Cyclophosphamide)",Taxotere + Carboplatin,25,30,15,40,55,65,8,50,42,70,2.5
